Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT05363826 | Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac® | unknown | Phase 1 | 30 | Photolitec LLCINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | terminated | Phase 1 | 16 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04205357 | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma(SAS-GKRS) | completed | Phase 1 | 24 | Haukeland University HospitalOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01269424 | BG & TMZ Therapy of Glioblastoma Multiforme | completed | Phase 1 | 10 | Stanton Gerson MDOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT01933815 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | suspended | Phase 1 / Phase 2 | 92 | Cortice Biosciences, Inc.INDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma(FOLAGLI) | terminated | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03867123 | A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients | completed | Phase 1 | 18 | Laminar PharmaceuticalsINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05737368 | Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | unknown | Phase 1 | 11 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 21, 2023 | clinicaltrials |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | terminated | Phase 1 | 3 | Daniel LandiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04642937 | Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma | unknown | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05700955 | Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 30 | University of LouisvilleOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03072134 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03355794 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | completed | Phase 1 | 19 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | unknown | Phase 1 / Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma | unknown | Phase 1 | 12 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05663125 | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas | unknown | Phase 1 / Phase 2 | 10 | Beijing Tiantan HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | terminated | Phase 1 / Phase 2 | 12 | Brown UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT01301430 | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.(ParvOryx01) | completed | Phase 1 / Phase 2 | 18 | Oryx GmbH & Co. KGINDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01865162 | Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study(KGDinGBM) | completed | Phase 1 | 6 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | withdrawn | Phase 1 / Phase 2 | 0 | Oblato, Inc.INDUSTRY | 0 | Oct 7, 2022 | clinicaltrials |
| NCT00687765 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 126 | SanofiINDUSTRY | 1 | Sep 14, 2022 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | University of RochesterOTHER | 0 | Aug 22, 2022 | clinicaltrials |
| NCT03722342 | TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma | unknown | Phase 1 | 9 | PharmAbcineINDUSTRY | 1 | Aug 17, 2022 | clinicaltrials |
| NCT02285959 | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme | unknown | Phase 1 | 30 | Global Neurosciences InstituteOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT01808820 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | completed | Phase 1 | 20 | Macarena De La Fuente, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02644291 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | completed | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT02330562 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | completed | Phase 1 / Phase 2 | 121 | CelgeneINDUSTRY | 2 | Jun 8, 2022 | clinicaltrials |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02709616 | Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)(PERCELLVAC) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT02808364 | Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)(PerCellVac2) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02871843 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas(G-FORCE-1) | completed | Phase 1 | 19 | EpicentRx, Inc.INDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 14, 2023source: clinicaltrials